Hi Havelots ( or soon to be),
The updated Sparks valuation soon to come to your door states a valuation on accepted Phase 2/3 MND study to be 89 cents, if it is addressed by the Healey platform the valuation is 94 cents.
Pre supposes commercialization by 1H 2026.
It only identifies one human condition to be treated that being ALS MND.
If we place Alzheimer's ( which is my preferred next target) we can go back to the good thingy of speculating a much different SP.
A mathematician of which we have a few, can now speculate a SP of 94 cents + triple that at least.
Kpax ( enjoy the ride)
Ann: PAA completes Phase 1 and files for Orphan Drug Designation, page-283
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.3¢ |
Change
0.038(18.3%) |
Mkt cap ! $95.01M | |||
| Open | High | Low | Value | Volume |
| 23.0¢ | 24.5¢ | 23.0¢ | $646.6K | 2.733M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 21242 | 24.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.5¢ | 496651 | 6 |
View Market Depth
| Last trade - 13.08pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
24.0¢ |
Change
0.038 ( 17.1 %) |
||||
| Open | High | Low | Volume | ||
| 24.0¢ | 24.5¢ | 23.0¢ | 983406 | ||
| Last updated 13.30pm 05/06/2024 ? | |||||
| PAA (ASX) Chart |